The Committee discusses and makes recommendations on the safety and effectiveness of Pfizer’s Biologics License Application (BLA) 125769 (STN 125769/0), ABRYSVO for active immunization for the prevention of acute respiratory disease and lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 60 years of age and older in a virtual meeting to be held on February 28 at 8:30 am. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PFE:
- Moderna, Pfizer: Top mRNA Innovator Stocks are Oversold
- Seagen price target raised to $210 from $180 at Oppenheimer
- FDA Virtual Vaccines & Related Biological Products Advisory Committee Meeting
- Pfizer acquisition of Seagen could add $7B in sales, says JPMorgan
- Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says
